Ipsen Pharma Company Profile by CMR

Company Profile

Ipsen Pharma Company Basic Information, and Sales Area

Item	Description
Company Name	Ipsen Pharma
Website	www.ipsen.com
Established Date	1929
Headquartered	Boulogne Billancourt
Market Position/ History	Ispen Pharma is based in France offers pipeline products across 115 countries with its presence in more than 30 countries. The company has R&D and manufacturing facilities located in China, France, Ireland, the United Kingdom, and the United States.
Sales Area	Worldwide
Contact Information	65 quai Georges Gorse Boulogne Billancourt, France Tel: +33-158335000

Business Segment/ Overview:

Ipsen Pharma is biopharmaceutical-based company which has diverse range of products such as carbometyx, cometriq, decapeptyl, dysport, increlex, nutropinAq. onivyde 9/irinotecan liposome injection, somatuline and xermelo. These products are offered under several therapeutic areas such as oncology, neuroscience, consumer healthcare, rare disease. The company invested $476.22 million in R&D, which is 14.9 % of sales.

Pipeline Portfolio:

The company has included pipeline products in their portfolio, which involves:
•   Carbometyx + atezolizumab- Phase 1 trial for solid tumors
•   IPN59011 longer acting neurotoxin Ax
•   IPN10200Longer-acting neurotoxin Ax / Tx
•   mesdopetam PD-LID for phase 2 trial
•   Onivyde 2L SCLC for phase 3 trials
•   Onivyde 1L PDAC2 for phase 3 trials
•   Elafibranor2 PBC for phase 3 trials

The company has invested in R&D activities in oncology, rare disease and neuroscience. Further, the company specializes in the areas of hepatocellular carcinoma, neuroendocrine tumors. prostate cancer, pancreatic cancer.

Onivyde, which received commercialization rights outside the U.S. and Taiwan. Onivyde is USFDA approved form of liposome used for treatment of patients with metastatic adenocarcinoma of pancreas a after disease progression following gemcitabine-based therapy. Limitation of Use: Onivyde is not indicated as a single agent for the treatment of patients with metastatic adenocarcinoma of the pancreas. It is also known as irinotecan liposome injection. (Onivyde) in combination with 5-fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) as a potential first-line treatment for metastatic pancreatic ductal adenocarcinoma cancer patients.

Recent Developments:

Year

Profile Details

Author Smruti Ransingh
Published 25 Jul 2023
Last Updated 23 Oct 2023
Reading Time~5 minutes
CoverageSWOT, Financials, Key Employees, History

- 1.1 About Ipsen Pharma
- 1.2 Key Facts
- 1.3 Key Employees
  - 1.3.1 Key Employee Biographies
- 1.4 History
- 1.5 Locations & Subsidiaries
  - 1.5.1 Head Office
  - 1.5.2 Other Locations & Subsidiaries
- 2.1 Company Overview
- 2.2 Business Segments
- 2.3 R&D Overview
- 2.4 Brands
- 2.5 Key Company Statistics
- 2.6 Key Financials (2015–2019)
- 2.7 Share Holder Analysis
- 2.8 Regional Presence
- 2.9 Services Offered
- 3.1 Strengths
- 3.2 Weaknesses
- 3.3 Opportunities
- 3.4 Threats
- 3.5 Key Competitors
- 4.1 Company Metrics
- 4.2 Key Investors
- 4.3 Recent Funding & Valuation
- 4.4 Historical Funding & Valuation
- 5.1 Acquisitions
- 5.2 Partnerships
- 6.1 Latest News & Announcements
- 6.2 Strategic Initiatives
- 7.1 Summary of Findings
- 7.2 Strategic Recommendations

Get a Custom Profile

Need a tailored company profile or competitive intelligence report? Our analysts are ready to help.

Contact Our Experts

More Profiles

Explore all published company profiles across 30+ industry verticals.

View All Profiles

Ipsen Pharma Company Profile